UNSW -- Millions of people world-wide who have contracted a highly resistant strain of HIV could benefit from a new drug to treat the infection, according to UNSW research. Co-authored by UNSW’s National Centre in HIV Epidemiology and Clinical Research (NCHECR), the research shows that the majority of patients who have not responded to traditional treatments have had good results from a new combination therapy involving raltegravir.
